Literature DB >> 34006878

Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women.

Oana A Zeleznik1, Raji Balasubramanian2, Yibai Zhao2, Lisa Frueh3, Sarah Jeanfavre4, Julian Avila-Pacheco4, Clary B Clish4, Shelley S Tworoger5, A Heather Eliassen3,6.   

Abstract

Known modifiable risk factors account for a small fraction of premenopausal breast cancers. We investigated associations between pre-diagnostic circulating amino acid and amino acid-related metabolites (N = 207) and risk of breast cancer among predominantly premenopausal women of the Nurses' Health Study II using conditional logistic regression (1057 cases, 1057 controls) and multivariable analyses evaluating all metabolites jointly. Eleven metabolites were associated with breast cancer risk (q-value < 0.2). Seven metabolites remained associated after adjustment for established risk factors (p-value < 0.05) and were selected by at least one multivariable modeling approach: higher levels of 2-aminohippuric acid, kynurenic acid, piperine (all three with q-value < 0.2), DMGV and phenylacetylglutamine were associated with lower breast cancer risk (e.g., piperine: ORadjusted (95%CI) = 0.84 (0.77-0.92)) while higher levels of creatine and C40:7 phosphatidylethanolamine (PE) plasmalogen were associated with increased breast cancer risk (e.g., C40:7 PE plasmalogen: ORadjusted (95%CI) = 1.11 (1.01-1.22)). Five amino acids and amino acid-related metabolites (2-aminohippuric acid, DMGV, kynurenic acid, phenylacetylglutamine, and piperine) were inversely associated, while one amino acid and a phospholipid (creatine and C40:7 PE plasmalogen) were positively associated with breast cancer risk among predominately premenopausal women, independent of established breast cancer risk factors.

Entities:  

Year:  2021        PMID: 34006878     DOI: 10.1038/s41523-021-00262-4

Source DB:  PubMed          Journal:  NPJ Breast Cancer        ISSN: 2374-4677


  68 in total

1.  Prospective serum metabolomic profiling of lethal prostate cancer.

Authors:  Jiaqi Huang; Alison M Mondul; Stephanie J Weinstein; Andriy Derkach; Steven C Moore; Joshua N Sampson; Demetrius Albanes
Journal:  Int J Cancer       Date:  2019-03-24       Impact factor: 7.396

2.  Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort.

Authors:  Laureen Dartois; Guy Fagherazzi; Laura Baglietto; Marie-Christine Boutron-Ruault; Suzette Delaloge; Sylvie Mesrine; Françoise Clavel-Chapelon
Journal:  Int J Cancer       Date:  2016-02-04       Impact factor: 7.396

3.  Population Attributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer.

Authors:  Rulla M Tamimi; Donna Spiegelman; Stephanie A Smith-Warner; Molin Wang; Mathew Pazaris; Walter C Willett; A Heather Eliassen; David J Hunter
Journal:  Am J Epidemiol       Date:  2016-12-06       Impact factor: 4.897

4.  Plasma Metabolomic Profiles and Risk of Advanced and Fatal Prostate Cancer.

Authors:  Ying Wang; Eric J Jacobs; Brian D Carter; Susan M Gapstur; Victoria L Stevens
Journal:  Eur Urol Oncol       Date:  2019-08-01

Review 5.  Metabolomics in cancer biomarker discovery: current trends and future perspectives.

Authors:  Emily G Armitage; Coral Barbas
Journal:  J Pharm Biomed Anal       Date:  2013-09-14       Impact factor: 3.935

Review 6.  Metabolomics in breast cancer: A decade in review.

Authors:  Amelia McCartney; Alessia Vignoli; Laura Biganzoli; Richard Love; Leonardo Tenori; Claudio Luchinat; Angelo Di Leo
Journal:  Cancer Treat Rev       Date:  2018-05-03       Impact factor: 12.111

7.  Proportion of invasive breast cancer attributable to risk factors modifiable after menopause.

Authors:  Brian L Sprague; Amy Trentham-Dietz; Kathleen M Egan; Linda Titus-Ernstoff; John M Hampton; Polly A Newcomb
Journal:  Am J Epidemiol       Date:  2008-06-13       Impact factor: 4.897

8.  Prospective metabolomics study identifies potential novel blood metabolites associated with pancreatic cancer risk.

Authors:  Xiang Shu; Wei Zheng; Danxia Yu; Hong-Lan Li; Qing Lan; Gong Yang; Hui Cai; Xiao Ma; Nathaniel Rothman; Yu-Tang Gao; Wei Jia; Yong-Bing Xiang; Xiao-Ou Shu
Journal:  Int J Cancer       Date:  2018-07-31       Impact factor: 7.396

9.  Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development.

Authors:  Jared R Mayers; Chen Wu; Clary B Clish; Peter Kraft; Margaret E Torrence; Brian P Fiske; Chen Yuan; Ying Bao; Mary K Townsend; Shelley S Tworoger; Shawn M Davidson; Thales Papagiannakopoulos; Annan Yang; Talya L Dayton; Shuji Ogino; Meir J Stampfer; Edward L Giovannucci; Zhi Rong Qian; Douglas A Rubinson; Jing Ma; Howard D Sesso; John Michael Gaziano; Barbara B Cochrane; Simin Liu; Jean Wactawski-Wende; JoAnn E Manson; Michael N Pollak; Alec C Kimmelman; Amanda Souza; Kerry Pierce; Thomas J Wang; Robert E Gerszten; Charles S Fuchs; Matthew G Vander Heiden; Brian M Wolpin
Journal:  Nat Med       Date:  2014-09-28       Impact factor: 53.440

10.  Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States.

Authors:  Paige Maas; Myrto Barrdahl; Amit D Joshi; Paul L Auer; Mia M Gaudet; Roger L Milne; Fredrick R Schumacher; William F Anderson; David Check; Subham Chattopadhyay; Laura Baglietto; Christine D Berg; Stephen J Chanock; David G Cox; Jonine D Figueroa; Mitchell H Gail; Barry I Graubard; Christopher A Haiman; Susan E Hankinson; Robert N Hoover; Claudine Isaacs; Laurence N Kolonel; Loic Le Marchand; I-Min Lee; Sara Lindström; Kim Overvad; Isabelle Romieu; Maria-Jose Sanchez; Melissa C Southey; Daniel O Stram; Rosario Tumino; Tyler J VanderWeele; Walter C Willett; Shumin Zhang; Julie E Buring; Federico Canzian; Susan M Gapstur; Brian E Henderson; David J Hunter; Graham G Giles; Ross L Prentice; Regina G Ziegler; Peter Kraft; Montse Garcia-Closas; Nilanjan Chatterjee
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

View more
  6 in total

1.  Lipoprotein and metabolite associations to breast cancer risk in the HUNT2 study.

Authors:  Julia Debik; Hartmut Schäfer; Trygve Andreassen; Feng Wang; Fang Fang; Claire Cannet; Manfred Spraul; Tone F Bathen; Guro F Giskeødegård
Journal:  Br J Cancer       Date:  2022-08-04       Impact factor: 9.075

2.  Small Molecule Signatures of Mice Lacking T-cell p38 Alternate Activation, a Model for Immunosuppression Conditions, after Total-Body Irradiation.

Authors:  Evan L Pannkuk; Evagelia C Laiakis; Jerry Angdisen; Meth M Jayatilake; Pelagie Ake; Lorreta Yun-Tien Lin; Heng-Hong Li; Albert J Fornace
Journal:  Radiat Res       Date:  2022-06-01       Impact factor: 3.372

3.  Metabolomic signatures of low- and high-adiposity neonates differ based on maternal BMI.

Authors:  Begum Aydogan Mathyk; Brian D Piccolo; Fernanda Alvarado; Kartik Shankar; Perrie O'Tierney-Ginn
Journal:  Am J Physiol Endocrinol Metab       Date:  2022-04-25       Impact factor: 5.900

4.  Intrapersonal Stability of Plasma Metabolomic Profiles over 10 Years among Women.

Authors:  Oana A Zeleznik; Clemens Wittenbecher; Amy Deik; Sarah Jeanfavre; Julian Avila-Pacheco; Bernard Rosner; Kathryn M Rexrode; Clary B Clish; Frank B Hu; A Heather Eliassen
Journal:  Metabolites       Date:  2022-04-20

5.  Prediagnostic Plasma Metabolomics and the Risk of Exfoliation Glaucoma.

Authors:  Jae H Kang; Oana Zeleznik; Lisa Frueh; Jessica Lasky-Su; A Heather Eliassen; Clary Clish; Bernard A Rosner; Louis R Pasquale; Janey L Wiggs
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

6.  Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide.

Authors:  Alessia Lodi; Renu Pandey; Jennifer Chiou; Ayon Bhattacharya; Shiliang Huang; Xingxin Pan; Brandon Burgman; S Stephen Yi; Stefano Tiziani; Andrew J Brenner
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.